

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Mia LEVITE

Serial No.:

10/809,425

Filed:

March 26, 2004

For:

Methods Of And Pharmaceutical Compositions For Modulating

T-Lymphocyte Adhesion, Migration, Gene Expression And Function By Glutamate And Analogs Thereof

Examiner: JALLA, SANJOO

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1644

Attorney

Docket: 27644

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin Moynihan

Registration No. 40,338

Dated: December 5, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

pond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, Complete if Known Substitute for form 1449 A PARA Application Number 10/809,425 INFORMATION DISCLOSURE Filing Date March 26, 2004 STATEMENT BY APPLICANT First Named Inventor Mia LEVITE Art Unit (use as many sheets as necessary) 1644 Examiner Name JALLA, SANJOO Sheet 1 of 2 Attorney Docket Number 27644 U.S. PATENT DOCUMENTS Cite No. 1 Examiner Publication Date MM-DD-YYYY Document Number Name of Patentee or Pages, Columns, Lines, Where Applicant of Cited Document Initials* Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (if known)} US-4,946,778 07-7-1990 Ladner et al.

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ . Number ⁴ . Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	2	PCT WO 99/50393	07-7-1999	Wank					
	ļ. <u></u>								
	1						$oxed{oxed}$		
	 						igspace		
	1						╨		
Ein		<u> </u>		<u> </u>	D :		Ш		
Examiner Signature					Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

-	Sut	ostitute for form 1449A/PTO	Complete if Known				
			Application Number 10/80				
	INF	ORMATION DISCLOSURE			26, 2004		
	STA	TEMENT BY APPLICANT	First Named Inventor				
	5171	TEMENT BY ATTEICANT	Group Art Unit 1644				
	1	(use as many sheets as necessary)		Examiner Name	JALLA	, SANJOO	
Sheet	2	Of	2	Attorney Docket Number	27644		
		OTHER PRIOR ART – NON I	PATENT LITER	ATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	3	Sperner-Unterweger et al. "T-Cell Subsets in Schizophrenia: A Comparison Between Drug-Naïve First Episode Patients and Chronic Schizophrenic Patients", Schizophrenia Research, 38: 61-70, 1999.					
	4	Schwartz et al. "Protective Autoimmunity: Regulation and Prospects for Vaccination After Brain and Spinal Cord Injuries", Trends in Molecular Medicine, 7(6): 252-258, 2001.					
	5	Schori et al. "T-Cell-Based Immunity Counteracts the Potential Toxicity of Glutamate in the Central Nervous System", Journal of Neuroimmunology, 119: 199-204, 2001.					
	6	Kuo et al. "The Involvement of Glutar Response", Journal of Neuroimmunol	ogy, 118: 245-25	5, 2001.	1	• .	
	7	Riewald et al. "Expression of Bomapi Normal/Malignant Hematopoiesis and 193", Blood, 91(4): 1256-1262, 1998.	l in the Monocyti		AML-		
	8	Levite "Nervous Immunity: Neurotran Function", Trends in Immunology, 22		ellular K+ and T-Cell			
	9	Levite "Neuropeptides, by Direct Inte and Break the Commitment to A Dist Sci. USA, 95: 12544-12549, 1998.					
	10	Nakanishi et al. "Glutamate Receptor Brain Research Reviews, 26: 230-235		and Signal Transduction	",		
	11	Yoles et al. "Protective Autoimmunity The Journal of Neuroscience, 21(11):	y Is A Physiologi		iuma",		
	12	Lombardi et al. "Characterization of I Lymphocytes", British Journal of Pha			1		

Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional).

'Applicant's unique citation designation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.